Revance Therapeutics Inc. (RVNC) has sought FDA approval for the expanded use of DAXXIFY in treating cervical dystonia in adults, and a decision is due on August 19, 2023.Cervical dystonia in adults is a chronic and debilitating neurologic condition affecting the muscles of the neck.DAXXIFY, the first and only peptide formulated neuromodulator, received its first FDA approval in September 2022, for the temporary improvement of moderate to severe glabellar lines in adults.For the first quarter ended Mar.31, 2023, DAXXIFY generated net product revenue of $15.4 million.RVNC closed Friday’s (Jul.28, 2023) trading at $22.53, up 2.32%.